Home > GSK620

molecules of the month

<< Back to March 2020

GSK620

Recent Publication

BD2 domain selective BET inhibitor

oral efficacy in 3 inflammation models

from SBDD of a BD2-selective HTS hit

Science, Mar. 19, 2020

GlaxoSmithKline, Stevenage, UK

GSK620 (GlaxoSmithKline (GSK) oral in vivo BD2 domain selective BET inhibitor)

get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more:

FREE CONTENT & PREMIUM TRIAL

Join Now

white

GSK620

get free samples and a Premium trial